Gladys Rodriguez

4.8k total citations
57 papers, 2.1k citations indexed

About

Gladys Rodriguez is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gladys Rodriguez has authored 57 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 14 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gladys Rodriguez's work include Cancer Treatment and Pharmacology (15 papers), Colorectal Cancer Treatments and Studies (10 papers) and Cancer therapeutics and mechanisms (9 papers). Gladys Rodriguez is often cited by papers focused on Cancer Treatment and Pharmacology (15 papers), Colorectal Cancer Treatments and Studies (10 papers) and Cancer therapeutics and mechanisms (9 papers). Gladys Rodriguez collaborates with scholars based in United States, France and Germany. Gladys Rodriguez's co-authors include John G. Kuhn, Howard A. Burris, Daniel D. Von Hoff, Geoffrey R. Weiss, John R. Eckardt, David Rinaldi, Suzanne M. Fields, Denise A. Yardley, Kathy D. Miller and James R. Woodworth and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Gladys Rodriguez

57 papers receiving 2.1k citations

Peers

Gladys Rodriguez

ONCOL

PRM

RNMI

John Hilton Canada

Grant Williams United Kingdom

Norbert Marschner Germany

Jane Bryce Italy

Wayne Rackoff United States

Anne M. Traynor United States

Vernon Harvey New Zealand

Manon Huizing Belgium

Paul R. Harnett Australia

John Hilton Canada

Gladys Rodriguez

1.2k ×0.8

ONCOL

828 ×1.5

616 ×1.2

PRM

300 ×0.8

RNMI

364 ×2.1

Citations per year, relative to Gladys Rodriguez Gladys Rodriguez (= 1×) peers John Hilton

Countries citing papers authored by Gladys Rodriguez

Since Specialization

Citations

This map shows the geographic impact of Gladys Rodriguez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gladys Rodriguez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gladys Rodriguez more than expected).

Fields of papers citing papers by Gladys Rodriguez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gladys Rodriguez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gladys Rodriguez. The network helps show where Gladys Rodriguez may publish in the future.

Co-authorship network of co-authors of Gladys Rodriguez

This figure shows the co-authorship network connecting the top 25 collaborators of Gladys Rodriguez. A scholar is included among the top collaborators of Gladys Rodriguez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gladys Rodriguez. Gladys Rodriguez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lund, J.C., Kyriakos P. Papadopoulos, Thomas Gribbin, et al.. (2023). Abstract 3855: Establishment and characterization of a panel of breast XPDX models representing innate or acquired resistance to trastuzumab deruxtecan (T-DXd). Cancer Research. 83(7_Supplement). 3855–3855. 1 indexed citations

Rodriguez, Gladys, et al.. (2023). Abstract P1-13-03: Establishment and characterization of two T-DM1-resistant, ER+/HER2+ breast XPDX models developed sequentially from the same patient with differential in vivo sensitivity to trastuzumab deruxtecan (DS-8201a). Cancer Research. 83(5_Supplement). P1–13. 1 indexed citations

Dixit, Niharika, et al.. (2020). Knowledge and self-efficacy for caring for breast and colon cancer survivors among safety net primary care providers. Supportive Care in Cancer. 28(10). 4923–4931. 9 indexed citations

Hurvitz, Sara A., Linda D. Bosserman, David Chan, et al.. (2014). Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer. SpringerPlus. 3(1). 244–244. 3 indexed citations

Rangel, Letícia Batista Azevedo, et al.. (2014). Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer. Breast Cancer Research and Treatment. 148(3). 571–580. 4 indexed citations

Krop, Ian E., Patricia LoRusso, Kathy D. Miller, et al.. (2012). A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine. Journal of Clinical Oncology. 30(26). 3234–3241. 274 indexed citations

Scagliotti, Giorgio V., Vera Hirsh, Salvatore Siena, et al.. (2012). Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study. Journal of Thoracic Oncology. 7(12). 1823–1829. 254 indexed citations

Smith, Lon, Gary B. Chisholm, Ronald Drengler, et al.. (2005). Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy. Breast Cancer Research and Treatment. 95(1). 13–16. 19 indexed citations

Rinaldi, David, John G. Kuhn, Howard A. Burris, et al.. (1999). A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemotherapy and Pharmacology. 44(5). 372–380. 158 indexed citations

10.

Rodriguez, Gladys, John G. Kuhn, Geoffrey R. Weiss, et al.. (1998). A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion. Investigational New Drugs. 16(1). 57–67. 2 indexed citations

11.

Gatzemeier, U., Gladys Rodriguez, Virginia L. Miller, et al.. (1998). Tirapazamine-cisplatin: the synergy. British Journal of Cancer. 77(S4). 15–17. 27 indexed citations

12.

Burris, Howard A., Véronique Dièras, Mehmet Tunca, et al.. (1997). Phase I study with the DNA sequence-specific agent adozelesin. Anti-Cancer Drugs. 8(6). 588–596. 22 indexed citations

13.

Weiss, Geoffrey R., Carl deMoor, David Rinaldi, et al.. (1996). A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer. Anti-Cancer Drugs. 7(4). 402–409. 3 indexed citations

14.

Eckhardt, S. Gail, Howard A. Burris, John R. Eckardt, et al.. (1996). A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Annals of Oncology. 7(5). 491–496. 34 indexed citations

15.

Woolley, Paul V., Carolyn J. Schultz, Gladys Rodriguez, et al.. (1996). A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma. Investigational New Drugs. 14(2). 219–222. 11 indexed citations

16.

Weiss, Geoffrey R., John G. Kuhn, Jinee Rizzo, et al.. (1995). A Phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 35(5). 397–402. 12 indexed citations

17.

Rinaldi, David, Howard A. Burris, F. Andrew Dorr, et al.. (1995). Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.. Journal of Clinical Oncology. 13(11). 2842–2850. 132 indexed citations

18.

Burris, Howard A., John G. Kuhn, Lee Smith, et al.. (1993). Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.. Journal of Clinical Oncology. 11(5). 950–958. 120 indexed citations

19.

Rodriguez, Gladys, Thomas D. Brown, Frank M. Balis, et al.. (1993). A phase I trial of trimetrexate (NSC352122) on a daily × 5 schedule in patients with refractory adult leukemia. Anti-Cancer Drugs. 4(2). 163–166. 3 indexed citations

20.

Burris, Howard A., Daniel D. Von Hoff, Gladys Rodriguez, et al.. (1992). A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anti-Cancer Drugs. 3(4). 337–346. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact